The E7 oncoprotein from Human Papilloma Virus (HPV) is an attractive candidate for anti-cancer vaccine development. In this study, we engineered HPV16 E7 coding sequence (wild type or mutagenized sequence, E7GGG) as fusions to β-1,3-1,4-glucanase (LicKM) of Clostridium thermocellum and produced in Nicotiana benthamiana plants using a transient expression system. Target antigens were purified and evaluated in mice for their potential as prophylactic and therapeutic vaccine candidates. Both fusion proteins induced E7-specific IgG and cytotoxic T-cell responses and protected mice against challenge with E7-expressing tumor cells. Furthermore, when administered after challenge, these plant-produced antigens prevented tumor development. © 2007 Elsevier Ltd. All rights reserved.
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Immunology and Microbiology(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases
Massa, S., Franconi, R., Brandi, R., Muller, A., Mett, V., Yusibov, V., & Venuti, A. (2007). Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine, 25(16 SPEC. ISS.), 3018 - 3021. https://doi.org/10.1016/j.vaccine.2007.01.018